What does a payer want to see before approving orforglipron?

The pharmacy is accredited and I have verified that on the accreditor register.

Everything I have found on this is either a forum aside or a product page, neither of which I trust.

I am comfortable with the arithmetic; what I am missing is the procedural detail around it.

What would you do, and what would you check afterwards?

The relevant point is that most denials cite a missing element rather than a clinical disagreement, and missing elements are fixable.

Track the deadlines. Appeal windows are finite, and a well-founded appeal filed late is worth nothing at all.

A peer-to-peer review — the prescriber speaking to the plan's reviewer — is available in many systems and resolves a meaningful proportion of denials that a written appeal would not.

A substantial proportion of denials cite incomplete documentation rather than clinical non-eligibility, which is why complete first submissions matter.

Research-use compounds are outside this framework entirely and are not approved for human use.

Evidence every criterion in the dated record, not in a covering letter.

Answering this needs the plan, since criteria vary and a general answer is not actionable.

Submit the supporting documents with the request rather than waiting to be asked. Requests denied for insufficient information are denials that a complete submission would have avoided.

Approvals expire. Note the renewal date when the approval arrives, because a lapse mid-treatment is administratively identical to a fresh denial.

The caveat is that this is administrative navigation and nothing here is clinical or legal advice.

The denial reason is the appeal specification. Address it directly.

The honest answer is that the process rewards preparation and punishes improvisation.

Obtain the medical policy for the specific drug and plan first. It lists the required diagnosis codes, thresholds, documented durations and any prerequisite therapy, and it is the checklist the reviewer works from.

The denial letter states a specific reason. The appeal should address that reason first and explicitly, with the missing evidence attached, rather than restating the original case.

Appeal windows and renewal periods are defined in plan documents and are strictly applied.

Processes differ by jurisdiction and by plan, so any general description will be wrong somewhere.

Diarise the renewal date the moment approval arrives.

Peer-to-peer review is available in many systems and is underused.

Each criterion must be evidenced in the clinical record, dated, before the request. A criterion asserted in a covering letter but absent from the notes is the commonest reason for a denial.

Peer-to-peer review is a standard step in utilisation-management processes and resolves a meaningful share of disputes.

A prescriber has to submit the request; this is a description of what makes one succeed, not a substitute for one.

Get the criteria first. A request written blind is a request written badly.

Start by obtaining the criteria before the request is submitted, because a request written blind is a request written badly.

Where prerequisite therapy is required, the record needs the agent, the dates, the dose and the reason it was stopped. "Tried and failed" without those four elements is not documentation.

Medical policies stating prior-authorisation criteria are published by plans and are obtainable before submission.

Attach everything on the first submission. Incomplete is the commonest denial.